RVL Pharmaceuticals to Host UPNEEQ® Overview and Business Update Webcast on January 19, 2022
01/18/2022 - 06:50 AM
-- Topics include corporate name change, launch plans into the medical aesthetics market and general business updates --
-- Featured speakers include Dr. Jackie Yee and Dr. Justin Harper --
Bridgewater, N.J., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (NASDAQ: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, announced today that Brian Markison, Chief Executive Officer and James “JD” Schaub, Chief Operating Officer, will host a video webcast to discuss recent UPNEEQ® trends, pending expansion into the medical aesthetics market and other general business updates.
Dr. Jackie Yee is board-certified in Plastic and Reconstructive Surgery and specializes in Aesthetic Injectables and Cosmetic Surgery based in Miami, Florida.
Dr. Justin Harper is an Aesthetic Physician and healthcare innovator with a diverse background encompassing plastic surgery, dermatology, and medical technology based in Columbus, Ohio.
Webcast details are as follows:
The webcast will be available thereafter via the Company’s website at www.rvlpharma.com
About RVL Pharmaceuticals plc 0.1% , for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults. UPNEEQ is the first non-surgical treatment option approved by the FDA for acquired blepharoptosis.
Investor and Media Relations for RVL Pharmaceuticals plc
Osmotica Pharmaceuticals Plc
OSMT Rankings
N/A Ranked by Stock Gains
OSMT Stock Data
Industry
Medicinal and Botanical Manufacturing
Sector
Manufacturing
Tags
Health Technology, Pharmaceuticals: Major, Manufacturing, Medicinal and Botanical Manufacturing
Country
US
City
Bridgewater
About OSMT
Osmotica Pharmaceuticals plc is a fully integrated biopharmaceutical company focused on the development and commercialization of specialty products that target markets with underserved patient populations. The company has a diverse portfolio consisting of promoted and non-promoted products, several of which incorporate Osmotica’s proprietary Osmodex® drug delivery system. RVL Pharmaceuticals, Inc. is the Company’s ophthalmic subsidiary supporting Upneeq®. Vertical Pharmaceuticals, LLC represents the Company’s diversified branded portfolio and Trigen Laboratories, LLC represents the Company’s non-promoted products, including complex generic formulations. Osmotica has operations in the United States, Argentina, and Hungary.
